+1.040 (+24.30%)
Range - - -   (-%)
Open -
Previous Close 4.280
Buy Price 4.760
Buy Volume -
Sell Price 4.980
Sell Volume -
Volume -
Value -
Measurement Type Value
EPS (USD) -1.288
Trailing EPS (USD) -1.22
NAV (USD) 1.045
Cash In Hand (USD) 1.439
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 5.091
Price / Cash In Hand 3.698
Issued & Paid-up Shares 18,108,300
Treasury Shares -
Market Cap (M) 96.336
Par Value (USD) n.a.
Beta - 75 Days 2.077
R-Squared - 75 Days(%) 6.22
Beta - 500 Days -1.332
R-Squared - 500 Days(%) 0.55
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 25 Feb 2021 05:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.


Release Date 11 Mar 2021
View All Events


Sunesis Pharmaceuticals, Inc. (Sunesis) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focuses primarily on the development of vosaroxin for the treatment of acute myeloid leukemia (AML). Vosaroxin is a anti-cancer quinolone derivative (AQD). AQDs have been shown to mediate anti-tumor activity by targeting mammalian topoisomerase II, an enzyme critical for cell replication. The Company owns worldwide development and commercialization rights to vosaroxin. The Company�s VALOR trial is designed to evaluate the effect of vosaroxin in combination with cytarabine, chemotherapy in AML. The trial has an adaptive design and is based on data from the Company's Phase II clinical trial of vosaroxin in combination with cytarabine in relapsed or refractory AML.

Loading Chart...